Allogene Therapeutics Inc ALLO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 03/18/24 EDT
4.20quote price arrow down-0.46 (-9.98%)
Volume
2,962,014
52 week range
2.23 - 6.89
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.20
  • 52 Week High6.89
  • 52 Week High Date05/15/23
  • 52 Week Low2.23
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap705.921M
  • Shares Out168.28M
  • 10 Day Average Volume3.58M
  • Dividend-
  • Dividend Yield-
  • Beta0.82
  • YTD % Change30.69

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.20
  • 52 Week High6.89
  • 52 Week High Date05/15/23
  • 52 Week Low2.23
  • 52 Week Low Date12/01/23
  • Market Cap705.921M
  • Shares Out168.28M
  • 10 Day Average Volume3.58M
  • Dividend-
  • Dividend Yield-
  • Beta0.82
  • YTD % Change30.69

RATIOS/PROFITABILITY

  • EPS (TTM)-2.09
  • P/E (TTM)-2.01
  • Fwd P/E (NTM)-2.51
  • EBITDA (TTM)-300.292M
  • ROE (TTM)-55.51%
  • Revenue (TTM)94,999.999
  • Gross Margin (TTM)-
  • Net Margin (TTM)-344,489.50%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Allogene Therapeutics Inc

 

Profile

MORE
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. It is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501...
Arie Belldegrun M.D.
Executive Chairman of the Board
David Chang M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
Geoffrey Parker
Chief Financial Officer, Executive Vice President, Principal Financial Officer, and Principal Accounting Officer
Timothy Moore
Executive Vice President, Chief Technical Officer
Zachary Roberts M.D., Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Earl Douglas Esq.
General Counsel
Address
210 East Grand Avenue
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
CABA
Cabaletta Bio Inc
17.98-0.76-4.06%
AVTE
Aerovate Therapeutics Inc
26.39-0.31-1.16%
COGT
Cogent Biosciences Inc
6.74-0.31-4.40%
ATXS
Astria Therapeutics Inc
15.61+0.15+0.97%
FUSN
Fusion Pharmaceuticals Inc
10.64+0.65+6.51%